ImmunityBio Beheer

Beheer criteriumcontroles 4/4

De CEO ImmunityBio is Rich Adcock, benoemd in Oct2020, heeft een ambtstermijn van 3.58 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 1.16M, bestaande uit 68.8% salaris en 31.2% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.035% van de aandelen van het bedrijf, ter waarde € 1.26M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 3.6 jaar en 4.2 jaar.

Belangrijke informatie

Rich Adcock

Algemeen directeur

US$1.2m

Totale compensatie

Percentage CEO-salaris	68.8%
Dienstverband CEO	4yrs
Eigendom CEO	0.03%
Management gemiddelde ambtstermijn	3.6yrs
Gemiddelde ambtstermijn bestuur	4.2yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Rich Adcock's beloning veranderd ten opzichte van ImmunityBio's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	-US$598m
Mar 31 2024	n/a	n/a	-US$601m
Dec 31 2023	US$1m	US$796k	-US$583m
Sep 30 2023	n/a	n/a	-US$458m
Jun 30 2023	n/a	n/a	-US$473m
Mar 31 2023	n/a	n/a	-US$430m
Dec 31 2022	US$4m	US$791k	-US$417m
Sep 30 2022	n/a	n/a	-US$400m
Jun 30 2022	n/a	n/a	-US$376m
Mar 31 2022	n/a	n/a	-US$370m
Dec 31 2021	US$29m	US$765k	-US$347m
Sep 30 2021	n/a	n/a	-US$323m
Jun 30 2021	n/a	n/a	-US$301m
Mar 31 2021	n/a	n/a	-US$264m
Dec 31 2020	US$843k	US$141k	-US$222m

Compensatie versus markt: De totale vergoeding ($USD 1.16M ) Rich } ligt onder het gemiddelde voor bedrijven van vergelijkbare omvang in de German markt ($USD 2.45M ).

Compensatie versus inkomsten: De vergoeding van Rich is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Rich Adcock (55 yo)

4yrs

Tenure

US$1,156,903

Compensatie

Mr. Richard Gerald Adcock, also known as Rich, has been the President of ImmunityBio, Inc. since March 05, 2021 and serves as its Director since March 29, 2021. He has been the Chief Executive Officer of I...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Patrick Soon-Shiong	Executive Chairman of the Board and Global Chief Scientific & Medical Officer	9.9yrs	US$865.34k	41.8% € 1.5b
Richard Adcock	President	4yrs	US$1.16m	0.035% € 1.3m
David Sachs	Chief Financial Officer	5.3yrs	US$1.06m	0.027% € 965.1k
Barry Simon	Chief Corporate Affairs Officer & Director	3.6yrs	geen gegevens	0.45% € 16.2m
Leonard Sender	Chief Operating Officer	4.6yrs	geen gegevens	geen gegevens
Regan Lauer	Chief Accounting Officer	2.9yrs	geen gegevens	0.014% € 489.8k
Enrique Diloné	Chief Technology Officer	1.8yrs	geen gegevens	geen gegevens
Jason Liljestrom	General Counsel & Corporate Secretary	3.3yrs	geen gegevens	geen gegevens
Sarah Singleton	Chief Communications Officer & Head of Patient Advocacy	4.6yrs	geen gegevens	geen gegevens
Sandeep Reddy	Chief Medical Officer	4.2yrs	geen gegevens	geen gegevens
Hans Klingemann	Chief Science Officer of Cellular	no data	geen gegevens	geen gegevens
Elizabeth Gabitzsch	Senior Vice President of Product Development & Vaccine Programs	1.2yrs	geen gegevens	geen gegevens

3.6yrs

Gemiddelde duur

56yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 26CA wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.6 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Patrick Soon-Shiong	Executive Chairman of the Board and Global Chief Scientific & Medical Officer	9.9yrs	US$865.34k	41.8% € 1.5b
Richard Adcock	President	3.6yrs	US$1.16m	0.035% € 1.3m
Barry Simon	Chief Corporate Affairs Officer & Director	17.8yrs	geen gegevens	0.45% € 16.2m
Christobel Selecky	Independent Director	4.2yrs	US$470.00k	0% € 0
Wesley Clark	Independent Director	3.7yrs	US$465.00k	0.0011% € 41.6k
Michael Blaszyk	Independent Director	9.3yrs	US$510.00k	0.038% € 1.4m
John Brennan	Independent Director	3.7yrs	US$472.50k	0.0036% € 129.9k
Cheryl Cohen	Lead Independent Director	5.3yrs	US$506.25k	0.029% € 1.0m
Linda Maxwell	Independent Director	3.6yrs	US$487.50k	0% € 0

4.2yrs

Gemiddelde duur

68yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 26CA wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.2 jaar).

ImmunityBio Beheer

Beheer criteriumcontroles 4/4

Belangrijke informatie

Recente managementupdates

ImmunityBio, Inc., Annual General Meeting, Jun 11, 2024

Insufficient new directors

ImmunityBio, Inc. Appoints Enrique Diloné as Chief Technology Officer, Effective August 14, 2023

Independent Director recently bought €66k worth of stock

ImmunityBio, Inc., Annual General Meeting, Jun 13, 2023

High number of new directors

Recent updates

ImmunityBio, Inc. Announces First Patients Dosed in Phase 1 Clinical Study of ImmunityBio’s CAR-NK Cell Therapy for the Treatment of Relapsed B-Cell Non-Hodgkin Lymphoma

New major risk - Financial position

Second quarter 2024 earnings released: US$0.20 loss per share (vs US$0.32 loss in 2Q 2023)

ImmunityBio, Inc.'s ANKTIVA® Now Covered by More Than a Dozen Insurance Plans Representing over 100 Million Lives Within Months of FDA Approval

ImmunityBio, Inc Announces Study of ANKTIVA® in Combination with the AdHER2DC Cancer Vaccine as a Potential Therapy to Control Endometrial Cancer

ImmunityBio, Inc. Announces the Initial Treatment of Multiple Patients in the United States to Receive Therapy with ANKTIVA

First quarter 2024 earnings released: US$0.20 loss per share (vs US$0.27 loss in 1Q 2023)

ImmunityBio, Inc. Completes GMP Drug Substance Manufacturing Sufficient for 170,000 Doses of ANKTIVA®

ImmunityBio, Inc., Annual General Meeting, Jun 11, 2024

ImmunityBio, Inc. Announces Positive Overall Survival Results of Anktiva Combined with Checkpoint Inhibitors in Non-Small Cell Lung Cancer

ImmunityBio, Inc. Announces FDA Approval of ANKTIVA®, First-in-Class IL-15 Receptor Agonist for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

Insufficient new directors

No longer forecast to breakeven

New minor risk - Profitability

Full year 2023 earnings released: US$1.15 loss per share (vs US$1.04 loss in FY 2022)

ImmunityBio Announces Data from A Phase 1 Pilot Study

ImmunityBio, Inc. Announces Full Accrual of First Two Phases of Cancer Vaccine Trial in Participants with Lynch Syndrome and Initiation of Randomized Controlled Phase of the Trial

Forecast to breakeven in 2026

Immunitybio, Inc. Announces Findings from Patient-Reported Outcomes (PROs) of Participants in the Phase 2/3 Quilt 3.032 Study of N-803 Plus BCG

New major risk - Financial position

Third quarter 2023 earnings released: US$0.19 loss per share (vs US$0.28 loss in 3Q 2022)

ImmunityBio, Inc. Announces First Data for Memory Cytokine-Enriched NK Cells in Small Cell Lung Cancer at SITC Meeting Show Promising Anti-Tumor Activity

ImmunityBio, Inc. Announces U.S. Food and Drug Administration Accepts its BLA Resubmission as Complete and Sets New PDUFA Date

ImmunityBio, Inc. Announces Biological License Application Resubmission for N-803 in BCG Unresponsive Non-Muscle-Invasive Bladder Cancer Carcinoma-In-Situ

New major risk - Shareholder dilution

ImmunityBio, Inc. announced that it has received $200 million in funding from Nant Capital, LLC

ImmunityBio, Inc. announced that it has received $200 million in funding from Nant Capital, LLC

Second quarter 2023 earnings released: US$0.32 loss per share (vs US$0.24 loss in 2Q 2022)

Jakubowitz Law Reminds Immunitybio Shareholders of A Lead Plaintiff Deadline of August 29, 2023

ImmunityBio, Inc. Appoints Enrique Diloné as Chief Technology Officer, Effective August 14, 2023

ImmunityBio, Inc. Announces Findings from a Phase 1 Study Showing Allogeneic Cytokine-Induced Memory-Like Natural Killer Cells

Pomerantz Law Firm Announces the Filing of a Class Action Against ImmunityBio, Inc. and Certain Officers – IBRX

Independent Director recently bought €66k worth of stock

ImmunityBio, Inc., Annual General Meeting, Jun 13, 2023

ImmunityBio, Inc. Receives Complete Response Letter from the U.S. Food and Drug Administration Regarding Its Biologics License Application

First quarter 2023 earnings released: US$0.27 loss per share (vs US$0.26 loss in 1Q 2022)

Full year 2022 earnings released: US$1.04 loss per share (vs US$0.89 loss in FY 2021)

ImmunityBio, Inc. announced that it expects to receive $50 million in funding

High number of new directors

Third quarter 2022 earnings released: US$0.28 loss per share (vs US$0.22 loss in 3Q 2021)

Second quarter 2022 earnings released: US$0.24 loss per share (vs US$0.23 loss in 2Q 2021)

ImmunityBio, Inc. Announces FDA Acceptance of Biologics License Application for N-803 in BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer Carcinoma in Situ

ImmunityBio, Inc. Announces Quilt Trial Results for BCG-Unresponsive Bladder Cancer and Advanced Metastatic Pancreatic Cancer

ImmunityBio, Inc. Submits Biologics License Application for N-803 Plus Bcg for Patients with Bcg-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma in Situ

First quarter 2022 earnings released: US$0.26 loss per share (vs US$0.21 loss in 1Q 2021)

ImmunityBio, Inc., Annual General Meeting, Jun 14, 2022

High number of new directors

Immunitybio Announces First Participants Have Been Enrolled in Lung-MAP Trial Studying Anktiva to Activate NK and T Cells in Non-Small Cell Lung Cancer

ImmunityBio, Inc. Announces Study Results That Further Demonstrate the Potential for Use of Memory-Like Cytokine-Enriched Natural Killer (m-ceNK) Cells for the Treatment of Cancer

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

ImmunityBio, Inc. Announces Study Results That Further Demonstrate the Potential for Use of Memory-Like Cytokine-Enriched Natural Killer (m-ceNK) Cells for the Treatment of Cancer

ImmunityBio, Inc. (NasdaqGS:IBRX) completed the acquisition of Dunkirk Manufacturing Facility and Certain Related Assets of Athenex, Inc. (NasdaqGS:ATNX).

ImmunityBio, Inc. Announces Positive Data from its Late-Stage Bladder Cancer Trial

ImmunityBio, Inc. Announces Promising Clinical Study Results for Kick and Kill HIV Cure Strategy to Reduce HIV Viral Load with Anktiva (N-803) Therapy

ImmunityBio, Inc. Announces Interim Results in its Metastatic Pancreatic Cancer Trial

ImmunityBio, Inc. Announces Updates on Its Clinical Year-End Review of Strategic Milestones

Third quarter 2021 earnings released: US$0.22 loss per share (vs US$0.17 loss in 3Q 2020)

ImmunityBio, Inc. Announces Positive Durable Responses in BCG Unresponsive Bladder Cancer Patients with A Complete Response Rate of 72%, Median Duration of Complete Response of 19.9 Months, and 85% Remaining Cystectomy-Free in Phase 2/3 Trial

ImmunityBio, Inc. Announces Authorization to Proceed with Phase 1/2/3 Randomized Trial in South Africa of Their Dual-Antigen T-Cell Vaccine as a Universal Boost in Previously Vaccinated Participants Against COVID-19

ImmunityBio, Inc.(NasdaqGS:IBRX) dropped from Russell 3000E Growth Index

Immunitybio, Inc. Receives FDA Authorization to Conduct A Phase 1B/2 Open-Label Study

ImmunityBio, Inc. Announces HIV Clinical Pipeline with Opening of a Phase 1 ‘HIV Cure Study’ in Patients Off Therapy and a Phase 2 Study in Acutely Infected Patients

Immunitybio, Inc. Expands Trials of T-Cell-Based Covid-19 Vaccine Candidate as A ‘Universal Boost’ in Vaccinated Subjects and Receives Approval to Test Intranasal Spray in South Africa

Board Member recently sold €1.6m worth of stock

FDA Authorizes ImmunityBio to Conduct Trial of its First-in-Human, Cryopreserved, Memory Cytokine-Enriched NK Cell Platform in Solid Tumors

Forecast to breakeven in 2025

ImmunityBio, Inc. Announces 78% Complete Response Following Chemotherapy-Free Combination of Il-15 Superagonist Anktiva with Rituxan in Relapsed Non-Hodgkin Lymphoma Patients

ImmunityBio, Inc. Announces Launch of Phase 2 Trial of IL-15 Superagonist Anktiva With Antiretroviral Therapy to Inhibit HIV Reservoirs

ImmunityBio Announces Positive Interim Phase I Safety Data of hAd5 T-Cell COVID-19 Vaccine Candidate in Oral and Sublingual Formulations